ACRX : Summary for AcelRx Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 1 hr 58 mins

AcelRx Pharmaceuticals, Inc. (ACRX)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.20+0.20 (+6.67%)
At close: 4:00PM EST
People also watch
ALIMAVEOAEGRECYTFOLD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.00
Open3.10
Bid2.05 x 100
Ask3.20 x 800
Day's Range3.05 - 3.20
52 Week Range2.40 - 4.50
Volume337,265
Avg. Volume226,072
Market Cap145.07M
Beta2.69
PE Ratio (TTM)-3.28
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017

    REDWOOD CITY, Calif., Feb. 27, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 mcg) for the treatment of patients with moderate-to-severe acute pain in a medically supervised setting. The acceptance of the NDA indicates that the FDA has deemed the application sufficiently complete to allow a substantive review.  The FDA has also set a Prescription Drug User Fee Act (PDUFA) date of October 12, 2017.  The PDUFA date is the target date set by the FDA to communicate its decision on the New Drug Application.

  • PR Newswire5 days ago

    AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017

    REDWOOD CITY, Calif., Feb. 23, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it will release fourth quarter and yearly financial results after market close on Thursday, March 2nd, 2017. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 2nd 2017 to discuss the financial results and provide a corporate update.

  • PR Newswire12 days ago

    AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Vincent J. Angotti has been appointed chief executive officer and a member of the company's board of directors, effective Monday, March 6, 2017. Mr. Angotti brings over two decades of experience leading executive and commercial teams at public and private life sciences companies, most recently as CEO of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for neuropathic pain and other neurological disorders. Mr. Angotti succeeds Howie Rosen, who will continue on the AcelRx board of directors, where he has served since 2008.